πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 65 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11135247

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG Β· Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11118177

Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosom

CRISPR THERAPEUTICS AG Β· Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11118196

Universal donor cells

CRISPR THERAPEUTICS AG Β· Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11118195

Universal donor cells

CRISPR THERAPEUTICS AG Β· Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11116798

Universal donor cells

CRISPR THERAPEUTICS AG Β· Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11116797

Universal donor cells

CRISPR THERAPEUTICS AG Β· Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11104918

Universal donor cells

CRISPR THERAPEUTICS AG Β· Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11083799

Materials and methods for treatment of hereditary haemochromatosis

CRISPR THERAPEUTICS AG Β· Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11071755

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG Β· Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11072792

Materials and methods for treatment of usher syndrome type 2A

CRISPR THERAPEUTICS AG Β· Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11013767

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG Β· Granted Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10995328

Materials and methods for treatment of autosomal dominant cone-rod dystrophy

CRISPR THERAPEUTICS AG Β· Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10881689

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG Β· Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10857184

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG Β· Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10736919

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10729725

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG Β· Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10662425

Materials and methods for treatment of autosomal dominant retinitis pigmentosa

CRISPR THERAPEUTICS AG Β· Granted Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted